EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence

Anna Keramida, Katerina Poprelka, Meropi Mousdi, Vasiliki Kotsali-Peteinelli, Maria-Ioanna Stefanou, Anastasios Bonakis, Georgios Tsivgoulis, Andreas Kyrozis, Panagiota-Eleni Tsalouchidou

Pharmaceuticals · 03.11.2026 · 19 (11) · 1744

DOI: 10.3390/ph19111744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 03.11.2026. Verfasst von Anna Keramida und 8 weiteren Autor:innen. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brivaracetam (BRV) is a synaptic vesicle protein 2A (SV2A) ligand approved for the treatment of focal-onset seizures. Its clinical use has increasingly expanded beyond approved indications and into understudied populations.

Objective

We aim to review BRV use beyond approved indications and in special populations.

Methods

MEDLINE, Embase, and Scopus were searched from inception to 30 April 2026. Eligible clinical studies were selected using prespecified criteria and synthesized narratively. Off-label status was determined separately under FDA and EMA labelling.

Results

The evidence consisted predominantly of observational studies, real-world cohorts, case series, and subgroup analyses of randomised trials. In genetic generalized epilepsies (GGE), BRV was associated with seizure reduction in several cohorts, whereas findings in developmental and epileptic encephalopathies (DEEs) were more heterogeneous. Real-world studies demonstrated the feasibility of BRV monotherapy, particularly following transition from levetiracetam. In status epilepticus (SE), intravenous BRV has been associated with SE cessation, although its independent contribution, optimal dose and timing, and role in treatment algorithms remain uncertain. Pregnancy and breastfeeding reports identified no clear safety signal, although exposure and long-term outcome data were scarce. Neonatal evidence was restricted largely to pharmacokinetic and short-term tolerability findings. Observational data indicated that psychiatric or behavioural adverse effects did not recur in some patients switched from levetiracetam; evidence in psychotic disorders remained particularly limited.

Conclusions

BRV may be useful in selected off-label settings and special populations. However, evidence remains limited and largely observational, so treatment decisions should be individualized. Prospective controlled studies and dedicated registries are needed.

Zitieren

APA

Keramida, A., Poprelka, K., Mousdi, M., Kotsali-Peteinelli, V., Stefanou, M., Bonakis, A., Tsivgoulis, G., Kyrozis, A., & Tsalouchidou, P. (2026). Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence. Pharmaceuticals, 19(11), 1744. https://doi.org/10.3390/ph19111744

Vancouver

Keramida A, Poprelka K, Mousdi M, Kotsali-Peteinelli V, Stefanou M, Bonakis A, et al. Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence. Pharmaceuticals. 2026;19(11):1744. doi:10.3390/ph19111744

BibTeX
@article{Keramida2026,
  author = {Keramida, Anna and Poprelka, Katerina and Mousdi, Meropi and Kotsali-Peteinelli, Vasiliki and Stefanou, Maria-Ioanna and Bonakis, Anastasios and Tsivgoulis, Georgios and Kyrozis, Andreas and Tsalouchidou, Panagiota-Eleni},
  title = {Brivaracetam in Off-Label Use and Special Populations: A Narrative Review of Current Evidence},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1744},
  doi = {10.3390/ph19111744}
}
Kostenlos starten →